Ute Schniegler-Mattox
Overview
Explore the profile of Ute Schniegler-Mattox including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
91
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muller T, Tasser C, Tesar M, Fucek I, Schniegler-Mattox U, Koch J, et al.
MAbs
. 2023 Aug;
15(1):2245519.
PMID: 37599441
A challenge when developing therapeutic antibodies is the identification of candidates with favorable pharmacokinetics (PK) early in development. A key determinant of immunoglobulin (IgG) serum half‑life is the efficiency of...
2.
Reusch U, Ellwanger K, Fucek I, Muller T, Schniegler-Mattox U, Koch J, et al.
Antibodies (Basel)
. 2022 Feb;
11(1).
PMID: 35225870
Innate cell engager (ICE) constructs are bispecific tetravalent antibodies targeting specific tumor antigens and simultaneously engaging natural killer (NK) cell and macrophage receptors for the destruction of tumor cells. Pre-complexing...
3.
Wingert S, Reusch U, Knackmuss S, Kluge M, Damrat M, Pahl J, et al.
MAbs
. 2021 Jul;
13(1):1950264.
PMID: 34325617
Epidermal growth factor receptor (EGFR)-targeted cancer therapy such as anti-EGFR monoclonal antibodies and tyrosine kinase inhibitors have demonstrated clinical efficacy. However, there remains a medical need addressing limitations of these...
4.
Ellwanger K, Reusch U, Fucek I, Wingert S, Ross T, Muller T, et al.
MAbs
. 2019 Jun;
11(5):899-918.
PMID: 31172847
Redirection of immune cells to efficiently eliminate tumor cells holds great promise. Natural killer cells (NK), macrophages, or T cells are specifically engaged with target cells expressing markers after infection...
5.
Mack M, Schniegler-Mattox U, Peters V, Hoffmann G, Liesert M, Buckel W, et al.
FEBS J
. 2006 Apr;
273(9):2012-22.
PMID: 16640564
The metabolic disease 3-methylglutaconic aciduria type I (MGA1) is characterized by an abnormal organic acid profile in which there is excessive urinary excretion of 3-methylglutaconic acid, 3-methylglutaric acid and 3-hydroxyisovaleric...